676 Rate, Characteristics and Predictors of Interval Colorectal Cancer After Colonoscopy Among Older Patients in the United States: A Population-Based Analysis of the SEER-Medicare Linked Database, 1998-2005

2011 ◽  
Vol 73 (4) ◽  
pp. AB142
Author(s):  
Yize R. Wang ◽  
John R. Cangemi ◽  
Michael F. Picco
2019 ◽  
Vol 156 (6) ◽  
pp. S-837-S-838
Author(s):  
Emad Mansoor ◽  
Chiara Maruggi ◽  
Mohannad Abou Saleh ◽  
Gerard A. Isenberg ◽  
Richard C. Wong ◽  
...  

2012 ◽  
Vol 58 (7) ◽  
pp. 2052-2060 ◽  
Author(s):  
Nadim S. Jafri ◽  
Milena Gould ◽  
Hashem B. El-Serag ◽  
Zhigang Duan ◽  
Jessica A. Davila

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 448-448
Author(s):  
Kabir Mody ◽  
Samuel O Antwi ◽  
David O Hodge ◽  
Zahara Meghji ◽  
Sikander Ailawadhi ◽  
...  

448 Background: Cholangiocarcinoma (CCA) is a rare, lethal cancer with five-year survival of less than 10%. Although incidence rates have been increasing in the United States, ethnic variations in survival have not been investigated. We examined multi-ethnic variation in overall survival (OS) and CCA-specific survival (CSS) using data from the population-based Surveillance Epidemiology and End Results (SEER) program in the four year periods before and after introduction of gemcitabine/cisplatin as treatment for CCA. Methods: The study included data from 9,975 CCA cases reported in SEER between 2006 and 2013. Multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (CIs) were calculated to examine overall and cholangiocarcinoma-specific survival by ethnicity, age, gender and in the pre- and post- gemcitabine/cisplatin era (2006-2009 vs. 2010-2013). Results: Compared to non-Hispanic Whites, Hispanics had poorer 3-year OS (HR = 1.18, 95% CI = 1.10-1.26) and 3-year CCA-specific survival (HR = 1.25, 95% CI = 1.16-1.35). Similarly, non-Hispanic Blacks had 3-year OS (HR = 1.22, 95% CI = 1.12-1.30) and 3-year CCA-specific survival (HR = 1.24, 95% CI = 1.13-1.37). Males and older patients also were found to have shorter survival compared to females and younger patients. Also noted was an increase in CCA incidence rate over time (2006-2013) of 5.93%. Among those < 50 versus ≥50 years old, a 23% higher rate of incidence in those < 50 was noted. Overall survival and CSS were both significantly improved for patients post-advent of Gemcitabine/Cisplatin. Statistically significant improvement in CSS pre- and post-advent of Gemcitabine/Cisplatin was noted in non-hispanic whites (p < 0.001) and Hispanics (p = 0.02). Conclusions: Hispanics and non-Hispanic Blacks have worse survival after diagnosis with CCA. Further studies are needed to determine the determinants of poor survival among these groups toward targeted intervention. Significant improvements in OS and CSS have been seen after the advent of Gemcitabine/Cisplatin. The incidence of CCA is rising faster in young persons, under the age of 50, compared with older patients.


Sign in / Sign up

Export Citation Format

Share Document